The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Frank Buttgereit - One of the best experts on this subject based on the ideXlab platform.
-
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis
Arthritis care & research, 2015Co-Authors: Maarten Boers, Frank Buttgereit, R Alten, A. Grahn, P. Rice, Kenneth G. Saag, D. Storey, John R. KirwanAbstract:Objective Little is known about the relationship between Morning symptoms of rheumatoid arthritis (RA) and measures of disease activity currently used to assess RA. Information available from the Circadian Administration of Prednisone in Rheumatoid Arthritis (CAPRA-2) study was used to investigate these relationships. Methods CAPRA-2 included 350 patients with RA who were symptomatic despite treatment with disease-modifying antirheumatic drugs, randomized 2:1 to additional treatment with a 5-mg daily dose of delayed-release prednisone or placebo. Pearson's correlations were used to evaluate the relationships between change from baseline in symptoms (duration of Morning Stiffness, severity of Morning Stiffness, and intensity of pain on waking) and measures of disease activity (the American College of Rheumatology 20% improvement criteria [ACR20], the Disease Activity Score in 28 joints [DAS28], and the Health Assessment Questionnaire disability index). Correlations were defined as weak ( 0.7). Results There was a strong correlation between the severity of Morning Stiffness and the intensity of Morning pain (Pearson's correlation 0.91, P < 0.001). There was a weak correlation between the duration of Morning Stiffness and measures of disease activity (0.24–0.28), with moderate correlations between the severity of Morning Stiffness or intensity of pain on waking and DAS28 or ACR20 scores (0.44–0.48). Severity of Morning Stiffness showed less variability and a greater effect size than did duration of Morning Stiffness. Conclusion Morning symptoms and measures of disease activity show weak to moderate correlations. Severity of Morning Stiffness showed less variability and greater effect size than did duration of Morning Stiffness. These findings suggest that severity is the preferred construct to measure the impact of Morning Stiffness in patients with RA, information that is not fully captured in the RA core set.
-
Morning Stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
Scandinavian journal of rheumatology, 2015Co-Authors: R Alten, Frank Buttgereit, Robert J. Holt, A. Grahn, P. Rice, J. Kent, A GibofskyAbstract:Objective: To assess Morning Stiffness in rheumatoid arthritis (RA) patients switched from immediate-release (IR) to delayed-release (DR) prednisone.Method: Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) is a 12-week, randomized, multicentre, active-controlled study of Morning Stiffness that consisted of a double-blind phase and a 9-month open-label extension. Patients receiving IR prednisone with no significant improvement after the double-blind study were switched to DR prednisone. Morning Stiffness duration and median absolute and relative changes in pain and global assessment were evaluated (3, 6, and 9 months).Results: In patients switched from IR to DR prednisone (n = 110), statistically significant reductions in Morning Stiffness occurred over 3 months and were sustained for 9 months. Absolute reduction of Morning Stiffness was ~50 min with > 40% relative reduction at each visit. Interleukin (IL)-6 levels were reduced by the same amount. Statistically significant and cli...
-
FRI0040 A Novel Approach to Quantify Morning Stiffness in Patients with Rheumatoid Arthritis
Annals of the Rheumatic Diseases, 2015Co-Authors: Heide Boeth, Georg N. Duda, Daniel Hinzmann, Sandra Hermann, William R. Taylor, Rainald Ehrig, Tom Witaschek, Frank ButtgereitAbstract:Background In addition to joint swelling and tenderness, patients with rheumatoid arthritis (RA) commonly experience Morning symptoms of joint Stiffness associated with pain that result in impaired function causing morbidity and productivity loss with early disease as well as those with low disease activity or remission1. However, the degree of Morning Stiffness has never been described. Objectives Although RA patients recognize Morning Stiffness as being one of the four most significant symptoms to manage, validated Morning Stiffness patient-reported outcome (PRO) measures are lacking. Therefore, we have developed an approach to objectively quantify finger joint Stiffness. The device has been approved by the ethical committee for the use in patients, and has also already obtained a national technical certification. We here present the first results of an ongoing study with this device. Methods So far, nine female postmenopausal RA patients affected by Morning Stiffness of at least one hour agreed to participate in this study and underwent repetitive measurements of evening and on following Morning cycle. These measurements quantified the passive resistance of an affected MCP joint against an externally applied torque while the finger was fixed in the device and passively moved from a completely extended position (referred to as 0°) to a flexed position of 60°. Measurement related sensors and advanced analysis algorithms for the investigation of resulting hysteresis curves enabled both the Stiffness and dissipated energy to be evaluated at definite flexion-extension angles. A one-way ANOVA was then applied to test for differences in both parameters between repetitive evening and Morning measurements. Results The Stiffness of the MCP joint (given in Nm/°) showed highest absolute values at extreme positions, i.e. at 0° and 60°, while lower values were detected at angles in between (Figure 1). At all flexion angles except 0°, Stiffness was – as expected – always more pronounced in the Morning (red bars) compared with evening measurements (blue bars). The difference found at 40° was statistically significant (p=0.038). Similar results (not shown) were obtained for dissipated energy with a significantly higher value in the Morning than in the evening at a flexion angle of 50° (p=0.047). Conclusions Even though the number of patients examined was low and the individual variation of absolute values between subjects is (known to be) considerable, our findings indicate that our approach is capable to differentiate Stiffness and dissipated energy in the Morning from that measured in the evening. The quantification of these parameters offers for the first time an option for objective evaluation the possibility to objectively evaluate and quantify this important patient-reported outcome in RA. Furthermore, such biomechanical assessments are also very likely able to quantify treatment effects on Morning Stiffness in the future. References Da Silva, JAP et al.: Impact of impaired Morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol. Vol. 125 (2011), pp. 6-11. Acknowledgements This study was funded by Horizon Pharma, USA. Disclosure of Interest H. Boeth: None declared, G. Duda: None declared, D. Hinzmann: None declared, S. Hermann: None declared, W. Taylor: None declared, R. Ehrig: None declared, T. Witaschek: None declared, F. Buttgereit Grant/research support from: Dr. Buttgereit received consultancy fees, honoraria and travel expenses from Merck Serono, Horizon Pharma (formerly Nitec Pharma) and Mundipharma International Ltd, and grant support from Merck Serono and Horizon Pharma
-
influence of rheumatoid arthritis related Morning Stiffness on productivity at work results from a survey in 11 european countries
Rheumatology International, 2015Co-Authors: Kalle Mattila, Frank Buttgereit, Risto TuominenAbstract:The objective of this study was to evaluate the influence of Morning Stiffness on productivity at work and to estimate the work-related economic consequences of Morning Stiffness among patients with RA-related Morning Stiffness in 11 European countries. The original sample comprised 1061 RA patients from 11 European countries (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden and UK). They had been diagnosed with RA and experience Morning Stiffness three or more times per week. Data were collected by interviews. Women comprised 77.9 % of the sample, the average age was 50.4 years, and 84.3 % had RA diagnosed for more than 2 years. Overall costs of RA-related Morning Stiffness was calculated to be 27,712€ per patient per year, varying from 4965€ in Spain to 66,706€ in Norway. On average, 96 % of the overall production losses were attributed to early retirement, with a markedly lower level (77 %) in Italy than in other countries (p < 0.0001). The proportion of patients who reported retirement due to Morning Stiffness and productivity losses due to late work arrivals and working while sick showed considerable variation across the countries represented in the study. Overall, the average annual cost of late arrivals (0.8 % of the total costs) was approximately half of the costs attributed to sick leave (1.7 %) and working while sick (1.5 %). Morning Stiffness due to RA causes significant production losses and is a significant cost burden throughout Europe. There seem to be notable differences in the impact of Morning Stiffness on productivity between European countries.
-
Influence of rheumatoid arthritis-related Morning Stiffness on productivity at work: results from a survey in 11 European countries
Rheumatology international, 2015Co-Authors: Kalle Mattila, Frank Buttgereit, Risto TuominenAbstract:The objective of this study was to evaluate the influence of Morning Stiffness on productivity at work and to estimate the work-related economic consequences of Morning Stiffness among patients with RA-related Morning Stiffness in 11 European countries. The original sample comprised 1061 RA patients from 11 European countries (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden and UK). They had been diagnosed with RA and experience Morning Stiffness three or more times per week. Data were collected by interviews. Women comprised 77.9 % of the sample, the average age was 50.4 years, and 84.3 % had RA diagnosed for more than 2 years. Overall costs of RA-related Morning Stiffness was calculated to be 27,712€ per patient per year, varying from 4965€ in Spain to 66,706€ in Norway. On average, 96 % of the overall production losses were attributed to early retirement, with a markedly lower level (77 %) in Italy than in other countries (p
H.-h. Najia - One of the best experts on this subject based on the ideXlab platform.
-
AB0358 Impact of Morning Stiffness Duration in Rheumatoid Arthritis Activity's Evaluation/Study Data QUEST-RA Morocco
Annals of the Rheumatic Diseases, 2014Co-Authors: S. Fanta, R. Samira, B. Rachid, A. Samir, H.-h. NajiaAbstract:Objectives To evaluate the impact of Morning Stiffness duration reported by the patient on the evaluation of rheumatoid arthritis activity. Methods A multi- national cross-sectional study that included 1129 patients with rheumatoid arthritis according to the 1987 ACR criteria. The Quest-RA (Quantitative Standard monitoring of patients with Rheumatoid Arthritis)” Morocco study was inspired from the Finnish study, including public and private rheumatologists over a period from January 2008 to December 2010. A pre- questionnaire with Socio- demographic, clinical and paraclinical was completed by all patients. The duration of the Morning Stiffness (MS) was evaluated from the time of awakening patients until the maximum improvement in pain. Four groups were established according to the disease activity (DAS28 values in and MS). We conducted correlation analysis to establish the relationship between MS and disease activity based on DAS28. Linear regression analysis was used to identify the determinants of this relationship. The ROC curve was used to differentiate between active and inactive forms in the MS and the DAS28. Results The average age of our patients was 48.82±12.72 years with a female predominance (87.3%). The median disease duration was 6 years (3-12). The mean DAS28 was 4.93±1.68, the length of the MS averaged 29.95±19.16 min. A significant correlation was noted between the DAS28 (r =0.318) VAS tired (r =0.343) overall VAS (r =0.315) ESR (r =0.144) and the duration of the MS (all p Conclusions Our study suggests that the MS reported by patients influences the disease activity assessed by the DAS28. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5567
-
ab0358 impact of Morning Stiffness duration in rheumatoid arthritis activity s evaluation study data quest ra morocco
Annals of the Rheumatic Diseases, 2014Co-Authors: S. Fanta, R. Samira, B. Rachid, A. Samir, H.-h. NajiaAbstract:Objectives To evaluate the impact of Morning Stiffness duration reported by the patient on the evaluation of rheumatoid arthritis activity. Methods A multi- national cross-sectional study that included 1129 patients with rheumatoid arthritis according to the 1987 ACR criteria. The Quest-RA (Quantitative Standard monitoring of patients with Rheumatoid Arthritis)” Morocco study was inspired from the Finnish study, including public and private rheumatologists over a period from January 2008 to December 2010. A pre- questionnaire with Socio- demographic, clinical and paraclinical was completed by all patients. The duration of the Morning Stiffness (MS) was evaluated from the time of awakening patients until the maximum improvement in pain. Four groups were established according to the disease activity (DAS28 values in and MS). We conducted correlation analysis to establish the relationship between MS and disease activity based on DAS28. Linear regression analysis was used to identify the determinants of this relationship. The ROC curve was used to differentiate between active and inactive forms in the MS and the DAS28. Results The average age of our patients was 48.82±12.72 years with a female predominance (87.3%). The median disease duration was 6 years (3-12). The mean DAS28 was 4.93±1.68, the length of the MS averaged 29.95±19.16 min. A significant correlation was noted between the DAS28 (r =0.318) VAS tired (r =0.343) overall VAS (r =0.315) ESR (r =0.144) and the duration of the MS (all p Conclusions Our study suggests that the MS reported by patients influences the disease activity assessed by the DAS28. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5567
Hiroshi Nakajima - One of the best experts on this subject based on the ideXlab platform.
-
Severity and Diurnal Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis
PloS one, 2016Co-Authors: Yoshihisa Kobayashi, Kei Ikeda, Takayuki Nakamura, Mieko Yamagata, Takuya Nakazawa, Shigeru Tanaka, Shunsuke Furuta, Takeshi Umibe, Hiroshi NakajimaAbstract:Background and objectives Although Morning Stiffness has long been recognized as a characteristic feature of rheumatoid arthritis (RA), it is no more included in the 2010 ACR/EULAR Classification Criteria or in the current major instruments for evaluating disease activity of RA. In this cross-sectional study, we aimed to determine the independent value and the optimal measurement of Morning Stiffness by clarifying the associations between Morning Stiffness and synovial inflammation. Patients and methods We enrolled 76 consecutive RA patients who underwent musculoskeletal ultrasound examination and agreed to participate in the study. In addition to asking the duration of Morning Stiffness, we asked patients to complete a diagram which represents the time course of their Morning Stiffness in the dominant hand. Based on this diagram, we calculated the severity and the diurnal improvement of Morning Stiffness. We also determined the activity of intra-articular synovitis in 11 joints and tenosynovitis in 8 tendons/tendon compartments in the same hand by using power Doppler (PD) ultrasound with a semiquantitative score (0–3). Results For intra-articular synovitis, swollen/tender joint counts more strongly correlated with total PD scores (ρ = 0.379–0.561, p ≤ 0.001) than did any parameters of Morning Stiffness (ρ = 0.217–0.314, p = 0.006–0.021). For tenosynovitis, however, the severity on awakening and the improvement of Morning Stiffness more strongly correlated with total PD scores (ρ = 0.503–0.561, p < 0.001) than did swollen/tender joint counts (ρ = 0.276–0.388, p = 0.001–0.016). Multivariate analyses identified the severity on awakening and the improvement but not the duration of Morning Stiffness as factors that independently associate with the total tenosynovial PD score. Conclusions Our data demonstrate a pathophysiological link between Morning Stiffness and tenosynovitis and also give an insight into the optimal measurement of Morning Stiffness. Our data support an independent value of evaluating Morning Stiffness in the management of RA.
-
AB0254 Severity and Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis
Annals of the Rheumatic Diseases, 2016Co-Authors: Yoshihisa Kobayashi, Kei Ikeda, Takayuki Nakamura, Mieko Yamagata, Takuya Nakazawa, Shigeru Tanaka, Shunsuke Furuta, Takeshi Umibe, Hiroshi NakajimaAbstract:Background Morning Stiffness has long been recognized by both patients and rheumatologists as a characteristic feature of rheumatoid arthritis (RA). However, Morning Stiffness is no more included in 2010 ACR/EULAR Classification Criteria for RA [1] or in major instruments for evaluating disease activity of RA such as Disease Activity Score (DAS) [2] and 2011 ACR/EULAR Provisional Definition of Remission [3] for the lack of solid evidence for its independent value. Objectives We aimed to clarify the associations between Morning Stiffness and synovial inflammation and determine the independent value and the optimal measurement of Morning Stiffness in patients with RA. Methods We enrolled 76 consecutive RA patients who underwent musculoskeletal ultrasound and agreed to participate in the study. In addition to asking the duration of Morning Stiffness, we asked patients to complete a diagram which represents the time course of their Morning Stiffness in the dominant hand. We also determined the activity of synovitis in 11 joints and tenosynovitis in 8 tendons/tendon compartments in the same hand by using power Doppler (PD) ultrasound with a semiquantitative score (0–3). Results Study patients were predominated by women (78.9%) with a mean age of 58.4 (SD 14.6) years and a median disease duration of 24 (IQR 8–63.75) months. Rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) had been positive in 84.2% and 77.6%, respectively. For synovitis, swollen/tender joint counts more strongly correlated with total PD scores (ρ=0.379–0.561, p≤0.001) than did any parameters of Morning Stiffness (ρ=0.217–0.314, p=0.006–0.021) (Table 1). For tenosynovitis, however, the severity on awakening and the improvement of Morning Stiffness more strongly correlated with total PD scores (ρ=0.503–0.561, p Conclusions Our data demonstrate a pathophysiological link between Morning Stiffness and tenosynovitis and also give an insight into the optimal measurement of Morning Stiffness. Our data support an independent value of evaluating Morning Stiffness in the management of RA. References Aletaha D, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. van der Heijde DM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916–20. Felson DT, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–13. Disclosure of Interest None declared
Risto Tuominen - One of the best experts on this subject based on the ideXlab platform.
-
Measuring the economic value of Morning Stiffness: consistency over 1 year
Scandinavian journal of rheumatology, 2015Co-Authors: S Tuominen, Mauri Leino, Laura Pirilä, Risto TuominenAbstract:Objectives: The aims of this study were to determine the within-patient variation in the duration of Morning Stiffness (MS) over 1 year and the corresponding monetary equivalents assigned to its changes using the willingness-to-pay (WTP) methodology.Method: A sample of 100 patients with rheumatoid arthritis (RA) was drawn from the register of the Hospital District of Southwest Finland. Subjects were interviewed by telephone on recruitment and 1 year later, using the same structured questionnaire. The subjects were asked to estimate in minutes the typical duration of their MS during the previous week. Sociodemographic background data and subjects’ WTP for a 25, 50, 75, and 100% reduction in MS duration were requested, and years with RA diagnosis and serological data were obtained from hospital records.Results: After 1 year, there was a reduction in average MS duration from 44.7 min to 39.0 min (ns); duration was reduced in 35% of patients, unchanged in 35%, and prolonged in 30%. Changes in MS duration were...
-
influence of rheumatoid arthritis related Morning Stiffness on productivity at work results from a survey in 11 european countries
Rheumatology International, 2015Co-Authors: Kalle Mattila, Frank Buttgereit, Risto TuominenAbstract:The objective of this study was to evaluate the influence of Morning Stiffness on productivity at work and to estimate the work-related economic consequences of Morning Stiffness among patients with RA-related Morning Stiffness in 11 European countries. The original sample comprised 1061 RA patients from 11 European countries (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden and UK). They had been diagnosed with RA and experience Morning Stiffness three or more times per week. Data were collected by interviews. Women comprised 77.9 % of the sample, the average age was 50.4 years, and 84.3 % had RA diagnosed for more than 2 years. Overall costs of RA-related Morning Stiffness was calculated to be 27,712€ per patient per year, varying from 4965€ in Spain to 66,706€ in Norway. On average, 96 % of the overall production losses were attributed to early retirement, with a markedly lower level (77 %) in Italy than in other countries (p < 0.0001). The proportion of patients who reported retirement due to Morning Stiffness and productivity losses due to late work arrivals and working while sick showed considerable variation across the countries represented in the study. Overall, the average annual cost of late arrivals (0.8 % of the total costs) was approximately half of the costs attributed to sick leave (1.7 %) and working while sick (1.5 %). Morning Stiffness due to RA causes significant production losses and is a significant cost burden throughout Europe. There seem to be notable differences in the impact of Morning Stiffness on productivity between European countries.
-
Influence of rheumatoid arthritis-related Morning Stiffness on productivity at work: results from a survey in 11 European countries
Rheumatology international, 2015Co-Authors: Kalle Mattila, Frank Buttgereit, Risto TuominenAbstract:The objective of this study was to evaluate the influence of Morning Stiffness on productivity at work and to estimate the work-related economic consequences of Morning Stiffness among patients with RA-related Morning Stiffness in 11 European countries. The original sample comprised 1061 RA patients from 11 European countries (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden and UK). They had been diagnosed with RA and experience Morning Stiffness three or more times per week. Data were collected by interviews. Women comprised 77.9 % of the sample, the average age was 50.4 years, and 84.3 % had RA diagnosed for more than 2 years. Overall costs of RA-related Morning Stiffness was calculated to be 27,712€ per patient per year, varying from 4965€ in Spain to 66,706€ in Norway. On average, 96 % of the overall production losses were attributed to early retirement, with a markedly lower level (77 %) in Italy than in other countries (p
-
Impact of Morning Stiffness on working behaviour and performance in people with rheumatoid arthritis
Rheumatology international, 2014Co-Authors: Kalle Mattila, Frank Buttgereit, Risto TuominenAbstract:Work disability remains a considerable problem for many patients with rheumatoid arthritis (RA). Morning Stiffness is a symptom of RA associated with early retirement from work and with impaired functional ability. We aimed to explore the patient’s perception of the impact of Morning Stiffness on the working life of patients with RA. A survey was conducted in 11 European countries. Patients of working age, with RA for ≥6 months and Morning Stiffness ≥3 Mornings a week, were interviewed by telephone using a structured questionnaire. Responses were assessed in the total sample and in subgroups defined by severity and duration of Morning Stiffness and by country. A total of 1,061 respondents completed the survey, 534 were working, 224 were retired and the rest were, i.e. homemakers and unemployed. Among the 534 working respondents, RA-related Morning Stiffness affected work performance (47 %), resulted in late arrival at work (33 %) and required sick leave in the past month (15 %). Of the 224 retired respondents, 159 (71 %) stopped working earlier than their expected retirement age, with 64 % giving RA-related Morning Stiffness as a reason. There was a differential impact of increasing severity and increasing duration of Morning Stiffness on the various parameters studied. There were notable inter-country differences in the impact of RA-related Morning Stiffness on ability to work and on retirement. This large survey showed that from the patient’s perspective, Morning Stiffness reduces the ability to work in patients with RA and contributes to early retirement.
-
FRI0442 Early retirement in patients with rheumatoid arthritis: Effect of Morning Stiffness
Annals of the Rheumatic Diseases, 2013Co-Authors: Risto Tuominen, Frank ButtgereitAbstract:Background Early Morning Stiffness in patients with rheumatoid arthritis (RA) may last for >1 hour in 23–49% of people. 1,2 It is associated with reduced quality of life and early retirement from work. 3,4 However little is known about how Morning Stiffness affects patients. Objectives A survey was conducted to assess the effect of Morning Stiffness on quality of life and patient withdrawal from the active work force. Methods A survey was conducted among working age patients (18 years to state retirement age) in 11 European countries (Belgium, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden, UK). Patients with RA for ≥6 months and RA-related Morning Stiffness were interviewed by telephone using a structured questionnaire, translated into the appropriate language. Results A total of 1061 patients (55 from Norway and approximately 100 from all other countries; 78% female) completed the questionnaires. Mean duration of Morning Stiffness was 1h 21 mins/day. Approximately seven in ten respondents reported that Morning Stiffness has a significant impact on their ability to work or do household tasks (69%) and limits the types of home/work jobs they can do (72%). More than four in ten respondents (42%) reported that Morning Stiffness has a major impact (score 7–10 on a scale of 1–10) on their daily lives, with a similar proportion (45%) reporting that a 30-min reduction in Morning Stiffness would significantly improve their quality of life. On average, respondents were willing to pay £4.35/day for a 30-min reduction in Morning Stiffness. Of the total respondents, 440 (41%) were not in full time work (part time work: 129; unemployed: 48; sick leave: 39; retired: 204; semi-retired: 20); for 53% of these respondents, this was directly due to RA. Seven in ten of the 224 retired/semi-retired respondents (71%) retired early, with Morning Stiffness playing a role in the decision for 64% of these patients.For more than half of the retired respondents, Morning Stiffness shortened their career (52%)and specifically lowered the age for retirement (56%). A quarter (23%) of retired/semi-retired respondents reported that better management of Morning Stiffness would allow them to return to work. Among the 621 respondents not currently completely retired or homemakers, 116 (19%) anticipated retiring early, with Morning Stiffness a factor in the decision for 61% of these patients. Conclusions The survey confirms the impact of Morning Stiffness on quality of life and the considerable contribution that the symptom makes to early retirement among patients with RA. The survey was conducted by Ipsos MORI and sponsored by an educational grant from Mundipharma International Limited References Khan et al. J Rheumatol 2009;36:2435–42. Yazici et al. J Rheumatol 2004;31:1723–6. da Silva et al. Scand J Rheumatol 2010; 40(Suppl 125): 6–11. Westhoff et al. Rheumatology 2008; 47: 980–4. Disclosure of Interest R. Tuominen Consultant for: Mundipharma International Limited, Speakers Bureau: Mundipharma International Limited, F. Buttgereit Grant/Research support from: Merck Serono, Horizon Pharma, Consultant for: Merck Serono, Horizon Pharma, Mundipharma International Limited, Speakers Bureau: Merck Serono, Horizon Pharma, Mundipharma International Limited
Timo Möttönen - One of the best experts on this subject based on the ideXlab platform.
-
How much is a reduction in Morning Stiffness worth to patients with rheumatoid arthritis
Scandinavian Journal of Rheumatology, 2011Co-Authors: Risto Tuominen, S Tuominen, Timo MöttönenAbstract:Objective: The aim of this study was to determine the monetary equivalent of the emotional and functional impact of Morning Stiffness (MS) in patients with rheumatoid arthritis (RA), using alternative valuing methods.Methods: Telephone interviews were conducted among 166 patients with RA to assess utility and clinical symptoms, including MS. Three standard economic methods were used: the human capital approach (HCA), marginal value of time (MVT), and willingness-to-pay (WTP).Results: The monetary equivalent of the impact of MS varied with the method used (from EUR 5.74 to EUR 17.87 per patient per day) and severity of MS (5–8-fold higher in patients with severe MS compared with mild MS). Patients placed considerable value on a reduction in duration and severity of MS. Patients with MS lasting an hour or more were willing to pay EUR 21.74/day to stop the symptom and EUR 10.63/day to halve the duration. Patients with severe MS were willing to pay EUR 47.86/day to stop the symptom and EUR 21.68/day to halve ...
-
How much is a reduction in Morning Stiffness worth to patients with rheumatoid arthritis?
Scandinavian journal of rheumatology. Supplement, 2011Co-Authors: Risto Tuominen, S Tuominen, Timo MöttönenAbstract:The aim of this study was to determine the monetary equivalent of the emotional and functional impact of Morning Stiffness (MS) in patients with rheumatoid arthritis (RA), using alternative valuing methods. Telephone interviews were conducted among 166 patients with RA to assess utility and clinical symptoms, including MS. Three standard economic methods were used: the human capital approach (HCA), marginal value of time (MVT), and willingness-to-pay (WTP). The monetary equivalent of the impact of MS varied with the method used (from EUR 5.74 to EUR 17.87 per patient per day) and severity of MS (5-8-fold higher in patients with severe MS compared with mild MS). Patients placed considerable value on a reduction in duration and severity of MS. Patients with MS lasting an hour or more were willing to pay EUR 21.74/day to stop the symptom and EUR 10.63/day to halve the duration. Patients with severe MS were willing to pay EUR 47.86/day to stop the symptom and EUR 21.68/day to halve the severity. The observed variation in the monetary equivalent of the impact of MS obtained with the three estimation methods indicates that the findings of studies using different valuing methods should not be compared directly. The study demonstrates that a reduction in MS is worth a considerable amount to patients with RA, particularly those with severe or prolonged MS. These findings suggest that clinical treatment decisions to improve patients' quality of life should also incorporate therapy that reduces MS.